The data shows that 19.1% of workers screened via hair samples tested positive, with marijuana acting as the primary driver. Marijuana positivity within this testing category climbed to 15.1% in 2025, a 58.9% surge over the last five years. While overall urine drug test positivity remained stagnant at 4.3%, the hair analysis results suggest a deeper, chronic pattern of use among a significant portion of the workforce.

Industry-specific data reveals that healthcare workers recorded the highest overall positivity rate at 5.8%, while the retail trade sector led in marijuana-specific findings at 7.6%. Beyond cannabis, other substances showed troubling upward trends; cocaine positivity reached 4.0% and amphetamines rose to 2.3%. These figures underscore a shift in how employers track impairment, particularly as hair and oral fluid tests gain traction for being more resistant to tampering than standard urine specimens.

Despite the broader rise in positive results, the report identified a sharp decline in fentanyl usage, which dropped by nearly half to 0.28% in 2025. Experts attribute this positive shift to increased employer deterrence strategies and education. As federal discussions regarding the reclassification of marijuana continue, the disparity between testing methods remains a focal point for organizations attempting to balance workplace safety with evolving substance use patterns.